Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01026337 · ClinicalTrials.gov registry record
Magnetic Resonance Imaging (MRI) in Predicting Response to Sunitinib Malate in Patients With Locally Advanced or Metastatic Kidney Cancer
A clinical trial, sponsored by Abramson Cancer Center at Penn Medicine.
- Completed
- Registry status
- 43
- Enrollment target
NCT01026337 is a clinical trial that has completed, run by Abramson Cancer Center at Penn Medicine. The registered enrollment target is 43 participants.
The verdict
NCT01026337 has completed, sponsored by Abramson Cancer Center at Penn Medicine.
- COMPLETED
- Registry status
- 43 participants
- Enrollment target
Study Summary
Rationale: Diagnostic procedures, such as MRI, may help doctors predict a patient's response to treatment and help plan the best treatment. Purpose: This clinical trial is studying MRI in predicting response to sunitinib malate in patients with locally advanced or metastatic kidney cancer.
Interventions
- GENETIC mutation analysis
- OTHER immunohistochemistry staining method
- OTHER pharmacological study
- PROCEDURE dynamic contrast-enhanced magnetic resonance imaging
- DRUG sunitinib malate
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2009-04 |
| Est. Completion | 2018-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01026337
The ClinicalTrials.gov registry entry for NCT01026337 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Abramson Cancer Center at Penn Medicine, which has 402 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which mutation analysis is the first listed.
NCT01026337 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01026337 about?
NCT01026337 is a clinical study titled "Magnetic Resonance Imaging (MRI) in Predicting Response to Sunitinib Malate in Patients With Locally Advanced or Metastatic Kidney Cancer". Rationale: Diagnostic procedures, such as MRI, may help doctors predict a patient's response to treatment and help plan the best treatment. Purpose: This clinical trial is studying MRI in predicting response to sunitinib malate in patients with locally advanced or metastatic kidney cancer.
What is the current status of trial NCT01026337?
This trial is currently completed. The enrollment target is 43 participants. The study started on 2009-04. Estimated completion is 2018-11.
What interventions are being tested in trial NCT01026337?
The interventions under investigation include: mutation analysis (GENETIC), immunohistochemistry staining method (OTHER), pharmacological study (OTHER), dynamic contrast-enhanced magnetic resonance imaging (PROCEDURE), sunitinib malate (DRUG).
Who is sponsoring clinical trial NCT01026337?
This trial is sponsored by Abramson Cancer Center at Penn Medicine, which has 402 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.